Scottish Medicines Consortium bezlotoxumab (Zinplava)

Scottish Medicines Consortium bezlotoxumab (Zinplava)

in the absence of a submission from the holder of the marketing authorisation:

bezlotoxumab (Zinplava®) is not recommended for use within NHS Scotland.

Indication under review: Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Name: bezlotoxumab (Zinplava)
SMC Drug ID: 1293/17
Manufacturer: MSD
Indication: Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 11 December 2017

To read more Press Release articles, click here.